IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
24 April 2024 - 2:00PM
IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical
company developing innovative gamma-delta T cell therapies, today
announced an oral presentation at the American Society of Gene
& Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7
– 11, 2024, in Baltimore, MD and virtually.
Details of the oral presentation are as follows:
Title: Healthy Donor vs Patient Manufactured Autologous Deltex
DRI Product; Immunophenotyping Gene Expression
Session Type: In-Person Oral Presentation
Session Title: Novel Production Platforms
Abstract Number: 282
Location: Ballroom 2
Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm
ET
Abstracts are available at https://annualmeeting.asgct.org/. The
data are embargoed until 6:00 a.m. ET on the presentation day,
Wednesday May 10, 2024. A copy of the presentation will be
available at https://in8bio.com once the presentation
concludes.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing
gamma-delta T cell-based immunotherapies for cancer patients.
Gamma-delta T cells are a specialized population of T cells that
possess unique properties, including the ability to differentiate
between healthy and diseased tissue. The company’s lead program,
INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM).
Additional programs include Phase 1 trials in solid and hematologic
tumors, including INB-200 for GBM and INB-100 for patients with
hematologic malignancies undergoing transplantation. For more
information about IN8bio, visit www.IN8bio.com.
Corporate Contact:IN8bio, Inc.Glenn Schulman, PharmD,
MPH203.494.7411gdschulman@IN8bio.com
InvestorsMeru AdvisorsLee M. Sternlstern@meruadvisors.com
Media ContactKimberly HaKKH
Advisors917.291.5744kimberly.ha@kkhadvisors.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024